Table 3.
PPA of the SARS-CoV-2 PSV assay with vaccinated individuals.
| Vaccine positive percentage agreement (PPA) | |
|---|---|
| Specimens from vaccinated individuals (pre-booster) | |
| Median days postinitial injection: 22.5 days | |
| IQR: 16.25–28.75 days | |
| Median SARS-CoV-2 ID50 titer: 285 | |
| ID50 IQR: 141–485 | |
| Metric | SARS-CoV-2 PSV |
| Vaccinated | 24 |
| Positive on assay | 21 |
| PPA | 87.5% |
| Specimens from vaccinated individuals (post-booster) | |
| Median days postinitial injection: 37 days | |
| IQR: 34–38 days | |
| Median SARS-CoV-2 ID50 titer: 597 | |
| ID50 IQR: 359–1032.3 | |
| Metric | SARS-CoV-2 PSV |
| Vaccinated | 71 |
| Positive on assay | 70 |
| PPA | 98.6% |